This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

HIGHLIGH S OF PRESCRIBING INFORMAT ON

hese highlights do not include all the information needed to use DICLOFENAC POTASSIUM for ORAL SOLUT ON safely and effectively. See full prescribing information for DICLOFENAC POTASSIUM for ORAL SOLUT ON.

DICLOFENAC POTASSIUM for oral solution
Initial U.S. Appro a : 988

WARN NG: RISK OF SER OUS CARDIOVASCULAR AND GAS RO N ES INAL EVEN S
See u l prescr b ng information or comp ete boxed warning

Cardiovascular Risk
- Non-s eroidal anti-inflammatory d ugs (NSAIDs) may inc ease he r sk of serious ca diovascu ar (CV) thrombot c events, myocard al infarc ion, and stroke, which can be fatal. Risk may increase w th du at on of use. (5.1)
- Diclofenac Potass um for Oral Solut on s contraind cated for he reatment of peri-opera ive pain in he sett ng of coronary artery bypass graft (CABG) surgery. (4, 5.1)

Gastrointest nal Risk
- NSAIDs ncrease he risk of serious gastrointest nal (GI) adverse events inc uding b eeding, ulce at on, and perforat on of the stomach or intest nes, which can be fatal. Events can occur at any time without warn ng symptoms. E derly pa ients are at g eater r sk. (5 2)

NDICA IONS AND USAGE

D c ofenac Potass um for Oral Solu ion s a non-stero dal anti- nflammato y (NSAID) drug indicated for the acute treatment of migraine attacks w th or without au a in adu ts 18 years of age or older (1 1)

Impor ant Limitat ons (1.2):
- Diclo enac Potass um or Oral Solution is not indicated for the prophylact c therapy of migraine
- Sa ety and effec iveness of D c o enac Potass um for Oral Solution not estab ished for cluster headache, wh ch s present n an o der, predominantly male populat on

DOSAGE AND ADMINIS RA ION

S ngle 50 mg dose; mix sing e packet contents wi h 1 to 2 ounces (30 to 60 mL) of wa er pr or to adm n s ra ion (1)

DOSAGE FORMS AND S RENG HS

Packets: Each con a n ng wh te to o f-wh te, flavored powder of dic ofenac potassium 50 mg in a so uble powder (3)

CON RAINDICA IONS
- Known hypersensit v ty to d c ofenac or NSAIDs (4)
- Pre-existing asthma, ur icar a, or a lergic-type reactions after aking asp rin or other NSAIDs (4)
- Use dur ng the peri-opera ive period n the setting of coronary ar ery bypass gra t (CABG) surgery (4, 5 1)

WARN NGS AND PRECAU ONS
- Serious and potent a ly fatal CV th ombot c events: Use lowest effec ive dose of Diclofenac Po assium or O al Solution or shor est possible duration (5 1)
- Se ious and po entia y fa al GI react ons: Use owest effect ve dose of Diclo enac Potass um for Oral Solut on for shortest possible durat on; use w th cau ion n patien s with prior history of ulcer d sease or GI b eed ng (5.2)
- Hepa ic e fects: Range from transam nase elevat ons to iver failure; discon inue Diclofenac Po assium or O al Solution mmediate y if abnormal l ver ests persist or worsen (5.3, 5.13)
- Hype tension: Can occur with NSAID trea ment. Moni or blood p essure close y du ing reatment w th Diclofenac Potassium for Oral So ut on (5.4)
- Congestive heart a lure and edema: Fluid retention and edema can occur with NSAID treatment; use D c ofenac Potassium for Oral So ut on w th caut on n pa ients w th fluid retent on or heart a lure (5.5)
- Renal effects: Long-te m adm n st at on of NSA Ds can result n enal pap l ary necros s and other renal inju y; use D c o enac Potassium for O al So ut on wi h caution n pat ents at risk (e g., the elder y, those w th renal impai ment, heart fa lure, iver impairment, and those tak ng d u et cs or ACE nhibitors) (5.6)
- Anaphylacto d react ons: May occur in patients w th the aspir n tr ad or n pat ents without prior exposure to Diclofenac Potass um for Oral Solution; d scontinue D c ofenac Potassium for O al So ut on immediately if an anaphy actoid reaction occurs (5.7)
- Serious skin react ons: Include ex o iative dermatit s, S evens-Johnson Synd ome, and tox c epide mal necro ys s, which can be fatal; discon inue Diclofenac Potassium or Oral Solution if rash or other signs of local skin reaction occur (5.8)

ADVERSE REAC IONS

Most common adve se react ons (≥1% and >placebo) were nausea and d zz ness (6 1)

o report SUSPEC ED ADVERSE REAC IONS contact Par Pharmaceu ical Inc at 1 800 828 9393 or FDA at 1 800 FDA 1088 or www fda gov/medwatch

DRUG IN ERAC IONS
- Aspir n: Concomitant administration w th other NSA Ds, inc uding asp rin, is not ecommended because of an inc eased risk of adverse react ons, inc uding GI bleeding (7 1)
- An icoagulan s: Concomitant use of diclofenac and an icoagulants (e.g., war ar n) increases the r sk of ser ous GI bleeding (7.2)

USE IN SPECIFIC POPULA IONS
- Pregnancy: Based on an mal data, may cause fetal harm. Based on human da a, s art ng at 30 weeks gestat on, D c ofenac Potassium for Oral Solution should be avoided as premature closure of the ductus arter osus n the fetus may occur (5.9, 8.1)
- Nurs ng Mo hers: Use with caut on, as it is not known if d c o enac s exc eted in human m lk (8.3)
- Hepatic nsu ficiency: The iver metabol zes almost 100% of d c ofenac; there is nsu ficient informat on avai able to suppo t dosing recommenda ions or Diclofenac Potassium for O al Solution in pa ients with hepa ic insuffic ency (5.3, 8.6, 12.3)

See 17 for PA EN COUNSELING NFORMA ION and Medication Guide

Issued: 07/2015

FULL PRESCRIBING INFORMAT ON: CON ENTS*

WARNING: RISK OF SER OUS C RDIOV SCULAR AND GAS ROIN ES INAL EVENTS
1 IND CAT ONS AND USAGE
c t atm t of M g a
2 Impo a t m at o s
2 DOS GE AND ADMINIS RA ION
2 c t atm t of M g a
2 2 o v so om t o m ato s of c of ac
3 DOS GE FORMS AND STRENGTHS
4 CONTRAINDICAT ONS
5 WARNINGS AND PRECAUTIONS
5 a d ovasc a ombot c v ts
5 2 ast o t st a ff c s s of U c ato d g a d fo at o
5 3 pat c ff c s
5 yp t s o
5 5 o g st v a t a a d d ma
5 6 a ff cts
5 ap y acto d act o s
5 8 S o s S act o s
5 9 g a cy
5 0 Mas g of I flammat o a d v
5 mato og ca f cts
5 2 Us at s W t x st t st ma
5 3 Mo to g
5 y to cs
6 AD ERSE RE CTIONS
6 ca st d s xp c w t c of ac otass m o a So to
6 2 dv s act o s po t d w t c of ac a d t NS I S
7 DRUG INTERACT ONS
sp
2 t coag a ts
3 l b to s
t cs
5 t m
6 M t ot xat
yc ospo
8 I b o s of ytoc om 50 2 9
8 USE IN SPECIFIC POPULATIONS
8 g a cy
8 2 abo a d v y
8 3 N s g Mot s
8 d at c Us
8 5 at c Us
8 6 pat c Impa m t
8 a Impa m t
10 O ERDOSAGE
11 DESCRIPTION
12 CLINIC L PHARMACOLOGY
2 M c a sm of ct o
2 3 a maco t cs
13 NON CLINIC L STUDIES
3 a c og s s M tag s s Impa m t of t ty
14 CLINIC L STUDIES
16 HOW SUPPL ED/S ORAGE AND HANDLING
17 PAT ENT COUNSELING INFORMA ION
a d ovasc a f cts
2 ast o t st a ff c s
3 patotox c ty
W g t a a d d ma
5 ap y acto d act o s
6 dv s S act o s
ff c s g g a cy
8 y to cs
9 pp ov d M d cat o d

*** Sections or subsections omitted from the fu l prescr bing information are not listed**

DICLOFENAC POTASS UM for oral solution
I07/15
49884 905

D CLOFENAC POT SS UM for oral solution
07/15
49884 905

FULL PRESCRIBING INFORMAT ON

WARNING: R SK OF SERIOUS CARDIOVASCULAR AND GASTROIN ES INAL E EN S

Cardio ascular Risk
- **Non steroidal anti inflammatory drugs (NS IDs) may increase the risk of serious cardio ascular (CV) thrombotic e ents, myocardial infarc ion, and stroke, which can be fatal. his risk may inc ease with duration of use. Patients with cardio ascular disease or risk factors for car io ascular isease may be at greater risk *[see* Warn ngs and Precautions (5 1)*]*.**
- **Diclofenac Potassium for Oral Solution is contrain icated for the treatment of peri operative pain in the setting of coronary artery bypass graft (CABG) surgery *[see* CON RAINDICA IONS (4) *and* Warn ngs and Precautions (5 1)*]*.**

Gastrointestinal Risk
- **NSA Ds increase the risk of serious gastrointes inal (GI) ad erse events inclu ing bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. hese e ents can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal e ents *[see* Warn ngs and Precautions (5 2)*]*.**

1 IND CAT ONS AND US GE

1.1 Acute Treatment of Migraine

c of ac otass m fo a So to s d cat d fo t ac t t atm t of m g a attac s w t o w t o t a a ad s 8 y a s of ag o o d

1.2 Impor ant Limitations
- c of ac otass m o a So to s ot d cat d fo t p op y act c t a y of m g a
- saf ty a d ff ct v ss of c of ac otass m fo a So to av ot b s ab s d fo c st adac w c s p s t a o d p dom a t y ma pop at o

2 DOS GE AND ADMINIS RA ION

2.1 Acute Treatment of Migraine

dm st o pac t 50 mg of c of ac otass m fo a So to fo t ac t t atm t of m g a mpty t co t ts of o pac t to a c p co ta g o 2 o c s 30 to 60 m of wat m x w a d d mm d at y o ot s q ds ot t a wat

a g c of ac o ass m fo a So to w t ood may ca s a d cto f ct v ss compa d to ta g c of ac otass m fo a So to o a mpty s omac *[see* **C in cal Pharmacology (12 3)***]*

Us t ow st ff ct v dos o t s o t st d ato co s st t w t d v d a pat t t atm t goa s saf ty a d f ct v ss of a s co d dos av ot b stab s d

2.2 Conversion From Other Formulations of Diclofenac

ff t fo m ato s of o a d c of ac g c of ac otass m fo a So to d c of ac sod m t c coat d tab s d c of ac sod m xt d d as tab s o d c of ac potass m mm d at as tab s may ot b b o q va t v ft m g am st gt s t sam o t s ot poss b to co v t dos g f om a y ot fo m ato of d c of ac o c of ac o ass m fo a So to

3 DOS GE FORMS AND STRENGTHS

c of ac otass m fo a So to s ava ab d v d a pac s ac d s g d to d v a 50 mg dos w m x d wat

4 CONTRAINDICAT ONS

c of ac otass m fo a So to s co t a d cat d pat ts w t ow yp s st v ty g a ap y ac o d act o s a d s o s s act o s to d c of ac *[see* **Warnings and Precautions (5 7 5 8)***]*

c of ac otass m fo a So to s co t a d cat d pat ts w o av xp c d ast ma t ca a o a g c typ act o s aft a g asp o ot NS I s S v som t m s fa a a ap y act c act o s o NS I s av b po t d s c pat ts *[see* **Warnings and Precautions (5 7 5 12)***]*

c of ac otass m fo a So to s co t a d cat d fo t t atm t of p op at v pa t s t g of co o a y a t y bypass g aft s g y *[see* **Warnings and Precautions (5 1)***]*

5 WARNINGS AND PRECAUTIONS

5.1 Car iovascular hrombotic Events

ca t as of s v a X 2 s ct v a d o s ct v NS I s of p t o t y a s d ato av s ow a c as d s of s o s ca d ovasc a V t ombot c v ts myoca d a facto a d st o w c ca b fata NS I s bot X 2 s ct v a d o s ct v may av a s m a s at ts w t ow V ds as o s acto s fo V ds as may b at g at s om m z t pot ta s fo a adv s V v t pat ts t at d w t a NS I s t ow st f ct v dos fo t s o t st d ato poss b ys c a s a d pat ts s o d ma a t o t d v opm t of s c v ts v t abs c of p vo s V symptoms I om pat ts abo t t s g s a d symptoms of s o s V v ts a d t st ps to a f t y occ

s o co s st t v d c t at co c t s of asp m t gat s t c as d s of s o s V t ombot c v s assoc at d w t NS I s co c t s of asp a d a NS I c as s t s of s o s I v s *[see* **Warnings and Precau ions 5 2)***]*.

wo a g co t o d c ca t as of a X 2 s ct v NS I fo t t atm t of pa t fi st 0 to days fo ow g co o a y a t y bypass g a t s g y fo d a c as d c d c of myoca d a facto a d st o *[see* **CON RAINDICA IONS (4)***]*.

5.2 Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation

NS I s c d g c of ac otass m fo a So to ca ca s s o s gast o t st a I adv s v ts s c as flammat o b d g c ato a d p fo ato of t stomac sma t st o a g t st w c ca b fata s s o s adv s v s ca occ at a y t m w t o w t o t wa g symptoms pat ts t at d w t NS I s y o fiv pat ts w o d v op a s o s pp I adv s v to NS I t apy s symptomat c Upp I c s g oss b d g o p o ato ca s d y NS I s occ app ox mat y % of pat ts t at d fo 3 to 6 mo t s a d abo t 2% to % of pat ts t at d fo o y a s t ds co t w t o g d ato of s t s c as g t ood of d v op g a s o s I v t at som t m d g t co s of t apy ow v v s o t t m NS I t apy s ot w t o t s

sc b NS I s c d g c of ac o ass m o a So to w t xt m ca to pat s w t a p o sto y of c d s as o I b d g at ts w t a p o sto y of p ptc c d s as a d/o gast o t st a b d g w o s NS I s av a g at t a 0 o d s fo d v op g a I b d t a pat ts w t t of t s s facto s t facto s t at c as t s fo I b d g pat ts t at d w t NS I s c d co com a t s of o a co t cost o ds o a t coag a s o g d ato of NS I t apy smo g s of a co o od ag a d poo g a at s at s Most spo ta o s po ts of fata I v ts a d y o d b tat d pat ts a d t o sp ca ca s o d b ta t at g t s pop at o

o m m z t pot ta s fo a adv s I v t pat ts t at d w t a NS I s t ow st ff ct v dos o t s o t st poss b d ato at ts a d p ys ca s s o d ma a t fo s g s a d symptoms of I c ato a d b d g d g c of ac otass m fo a So to t a y a d p ompt y t at add to a va ato a d t atm t f a s o s I adv s v t s s sp ct d s s o d c d d sco t ato of t c of ac otass m o a So to t a s o s I adv s v t s d o t o g s pat s a t at v t ap st at do ot c d NS I s s o d b co sd d

5.3 Hepatic Effects

vat o s of o o mo v t s s may occ d g t apy w t c of ac o ass m fo a So to s abo ato y ab o ma t s may p og ss may p s st o may o y b t a s t w t co t d t apy o d vat o s ss t a 3 t m s t pp m t of t o ma [U N] a g o g at vat o s of t a sam as s occ d abo t 5% of d c of ac t at d pat ts f t ma s of pat c f cto S s comm d d o t mo to g of v y

I c ca t as m a gf vat o s mo t a 3 t m s t U N of S S occ d abo t 2% of app ox mat y 5 00 pat ts at som t m d g t atm t was ot m as d a st d s I a op ab co t o d t a of 3 00 pat ts t at d fo 2 to 6 mo t s pat s w mo o d at 8 w s a d 200 pat ts w mo to d aga at 2 w s M a gf vat o s of a d/o S occ d abo t % of t 3 00 pat ts a d c d d ma d vat o s 8 t m s t U N abo t % of t 3 00 pat ts I t s op ab st dy a g c d c of bo d ss t a 3 t m s t U N mod at 3 o 8 t m s t U N a d ma d 8 t m s t U N vat o s of o S was obs v d pat ts c v g d c of ac w compa d to ot NS I s most a m a gf vat o s t a sam as s w d t ct d b o pat ts b cam symptomat c

b o ma t sts occ d d g t fi st 2 mo t s of t apy w t d c of ac 2 of t 5 pat ts a t as w o d v op d ma d t a sam as vat o s I postma t g po ts cas s of d g d c d patotox c ty av b po t d t fi st mo t a d som cas s t fi st 2 mo t s of NS I t apy b t ca occ at a y t m d g t atm t w t d c of ac

ostma t g s v a c as po t d cas s of s v pat c act o s c d g v c oss a d c f m a t pat ts w t a d w t o t a d c a d v fa Som of t s po t d cas s s t d fa a t s o v t a sp a tat o

M as t a sam as s a d S p od ca y pat s c v g o g t m t apy w t d c of ac b ca s s v pato ox c ty may d v op w t o t a p od om of d st g s g symp oms opt m m t m s o ma g t fi st a d s bs q t t a sam as m as m s a ot ow as d o c ca t a data a d postma t g xp c s t a sam as s s o d b mo to d w t o 8 w s aft t at g t atm t w t d c of ac

ow v s v pat c act o s ca occ at a y t m d g t atm t w t d c of ac If ab o ma v t sts p s st o wo s f c ca s g s a d/o symptoms co s st t w t v d s as d v op o f syst m c ma f stat o s occ g os op a as abdom a pa d a a da c d sco t c of ac otass m fo a So to mm d at y

o m m z t poss b ty t at pat c y w b com s v b tw t a sam as m as m ts o m pat ts of t wa g s g s a d symptoms of pa otox c ty g a s a fat g t a gy d a a p t s a d c g t pp q ad a t t d ss a d fl symptoms a d t app op at acto pat ts s o d ta f t s s g s a d symptoms app a

o m m z t pot ta s fo a adv s v at d v t pat ts t at d w t c of ac otass m fo a So to s t ow st f ct v dos fo t s o t st d ato poss b x c s ca to w p sc b g c of ac otass m fo a So to w t co com ta t d gs t at a ow to b pot ta y patotox c g ac tam op c a a t bo t cs a t p ptcs a to pat ts to avo d ta g o p sc pto ac tam op co a g p od cts w s g c of ac otass m fo a So to

5.4 Hypertension

NS I s c d g c of ac otass m fo a So to ca ad o w o s t o w o s g of p x st g yp t s o t of w c may co t b t o t c as d c d c of V v s Us NS I s c d g c of ac otass m fo a So to w t ca to pat s w t yp t s o Mo to b ood p ss c os y d g t tato of NS I t atm t a d t o g o t t co s of t apy

at ts ta g b o s t az d s o oop d t cs may av mpa d spo s to t s t ap s w ta g NS I s

5.5 Congestive Heart Fa lure and Edema

d t to a d d ma av b obs v d som pat ts ta g NS I s Us c of ac o ass m fo a So to w t ca to pat s w t fl d t to o a t fa

5.6 Renal Effects

Us ca to w t at g t atm t w t c of ac otass m fo a So to pat ts w t co s d ab d yd at o

o g t m adm st ato of NS I s as s t d a pap a y c o s s a d ot a y a tox c ty as a so b s pat ts w om a p ostag a d s av a comp sato y o t ma t a c of a p f so l t s pat s adm st ato of a NS I may ca s a dos d p d t d cto p ostag a d fo mat o a d s co da y a b ood flow w c may p c p at ov t a d comp sato at s at g at st s of t s act o a t os w t mpa d a f cto a t fa v dysf cto t os ta g d t cs o b to s a d t d y sco t ato of NS I t apy s s a y fo ow d by cov y to t p t atm t stat

No o mat o s ava ab f om co t o d c ca st d s ga d g t s of c of ac otass m fo a So to pat ts w t adva c d a d s as fo t atm t w t c of ac o ass m fo a So to s ot comm d d pat ts w t adva c d a d s as If c of ac o ass m fo a So to t apy m st b tat d c os mo to g of t pat ts a f cto s adv sab

5.7 Anaphylac oid Reactions

s w t ot NS I s a ap y acto d act o s may occ pat ts w t o t ow p o xpos to c of ac o ass m o a So to c of ac o ass m o a So to s co t a d cat d pat s w t t asp t ad s symptom comp x typ ca y occ s ast mat c pat ts w o xp c ts w t o w t o t asa po yps o w o x b ts v pot t a y fata b o c ospasm a t ta g asp o ot NS I s *[see* **CON RAINDICA ONS (4)***]*.

5.8 Serious Skin Reactions

NS I s c d g c of ac otass m fo a So to ca ca s s o s s adv s act o s s c as xfo at v d mat t s St v s o so Sy d om S S a d tox c p d ma c o y s s N w c ca b a a s s o s v ts may occ w t o t wa g I fo m pat ts abo t t s g s a d symp oms of s o s s ma f stat o s a d to d sco t c of ac otass m fo a So to at t fi st app a a c of s as o a y ot s g of yp s s t v ty

5 9 Pregnancy

c of ac otass m fo a So to ca ca s f a a m w adm st d to a p g a t woma S a t g at 30 w s g s at o c of ac o ass m fo a So to s o d b avo d d by p g a t wom as p mat c os of t d ct s at os s t f t s may occ If t s d g s s d d g t st m p od p g a cy t pat ts o d b app s d of t pot t a aza d to a f t s *[see* **Use in Special Popula ions (8 1)***]*.

5.10 Masking of Inflammation and Fe er

p a maco og ca act v ty of NS I s d c g flammat o a d poss b y f v may d m s t t y of t s d ag ost c s g s d t ct g comp cat o s of p s m d o f cto s pa f co d to s

5.11 Hematological Effects

m a may occ pat ts c v g NS I s s may b d to fl d t to occ to g oss l b ood oss o a comp t y d sc b d ff ct po yt opo ss l pat ts o g t m t a y w t NS I s c d g c of ac o ass m fo a So to c c mog ob o matoc t f t y x b t a y s g s o symp oms of a m a o b ood oss

NS I s b t pat t agg gat o a d av b s ow o p oo g b d g t m som pat ts U asp t NS I ff ct o pat t f cto s q a t tat v y ss of s o t d ato a d v s b a f y mo to pat ts t at d w t c of ac otass m fo a So to w o may b adv s y aff ct d y a t ato s pat t f cto s c as t os w t coag ato d so d s o pat s c v g a t coag a ts

5.12 Use in Patients Wi h Preexistent Asthma

at ts w t ast ma may av asp s s t v ast ma s of asp pat ts w t asp s s t v ast ma as b assoc at d w t s v b o c ospasm w c ca b fata S c c oss act v ty c d g b o c ospasm b tw asp a d ot NS I s as b po t d s c asp s s t v pat ts c of ac otass m fo a So to s co t a d cat d pat ts w t t s fo m of asp s s t v ty a d s o d b s d w t ca to a pat ts w t p x st g ast ma

5.13 Monitoring

ca s s o s l c ato s a d b d g ca occ w t o t wa g symptoms p ys c a s s o d mo to fo s g s o symp oms of l b d g

o pat ts o o g t m t atm t w t NS I s c d g c of ac o ass m o a So to p od ca y p fo m a a d c m st y p ofi sco t c of ac o ass m fo a So to f ab o ma v t sts o a t sts p ssto wo s

5.14 Pheny ketonurics

c of ac otass m fo a So to co ta s p y a a 22 5 mg p ac 50 mg pac t

6 ADVERSE REAC IONS

fo ow g s o s adv s act o s a d sc ss d s w t ab g
- a d ovasc a t ombot c v ts *[see* **BOXED WARNING** *and* **Warnings and Precautions (5 1)***]*
- ast o t st a ff cts *[see* **BOXED WARN NG** *and* **Warn ngs and Precautions (5 2)***]*
- pat c ff cts *[see* **Warnings and Precautions (5 3)***]*
- yp t s o *[see* **Warnings and Precautions (5 4]**
- o g st v a t a a d d ma *[see* **Warn ngs and Precautions (5 5)***]*
- a f cts *[see* **Warnings and Precautions (5 6)***]*
- ap y acto d act o s *[see* **Warn ngs and Precautions (5 7)***]*
- S o s S act o s *[see* **Warnings and Precautions (5 8)***]*

most commo adv s act o s po t d w t c of ac otass m fo a So to a a s a a d d zz ss

most commo adv s v ts s t g d sco t ato of pat ts fo ow g c of ac o ass m fo a So to dos g co to d c ca t as w t ca a 0 2% a d fl s g 0 2%

6.1 Clinical Stu ies Experience With Diclofenac Potassium for Oral Solution

ca s c ca t as a co d ct d d w d y va y g co d to s adv s act o at s obs v d t c ca t as of a d g ca ot b d ct y compa d w t at s t c ca t as of a ot d g a d may ot fl ct t at s obs v d p act c

saf ty of a s g dos of c of ac otass m o a So to was va at d 2 p ac bo co t o d t as w t a tota of 63 m g a pat s t at d w t c of ac otass m fo a So to fo a s g m g a adac o ow g t atm t w t d c of ac potass m t c of ac otass m fo a So to o d c of ac po ass m mm d at as tab ts [as a co t o] 5 s b cts 0 8% w t d w f om t st d s fo ow g p ac bo xpos s b ct 0 2% w t d w No w t d awa s w d to a s o s acto

most commo adv s act o s t at occ d % o mo of c of ac o ass m fo a So to t at d pat ts a d mo f q t w t c of ac otass m fo a So to t a w t pac bo w a s a a d d zz ss s **able 1**

Table : Treatment Related Ad erse Reactions With Incidence > % and Greater han Placebo in Stu ies 1 and 2 Combined

Disorder v t	**DICLOFENAC POTASS UM FOR ORAL SOLUTION** N=63	**Placebo** =6 6
Gastrointestinal Na s a	3%	2%
Nervous System zz ss	%	0 5%

6 2 Ad erse Reactions Reported With Diclofenac and Other NSAIDs

I pat ts a g d c of ac o ot NS I s t most f q ty po t d adv s act o s occ g app ox mat y % o 0% of pat ts a I act o s c d g abdom a pa co st pato d a a dysp ps a flat c g oss b d g/p o ato a t b a s a I c s [gast c/d od a] a d vom t g ab o ma a f cto a ma d zz ss d ma vat d v zym s adac s c as d b d g t m p t s as s a d t t s

dd to a adv s act o s po t d pat ts a g NS I s c d occas o a y

ody as a W o v f cto s p s s

a d ovasc a yst m o g st v a t fa yp t s o tac yca d a sy cop

g st v Syst m y mo t sop ag ts gast c/p pt c c s gast ts gast o t st a b d g g oss ts mat m s s pat ts a d c

m ca d ym atc yst m cc ymos s os op a op a m a p p a cta b d g stomat ts t omboc y op a

M tabo c a d N t t o a W g t c a g s

N vo s yst m x ty ast a co f so d p sso d am ab o ma t s d ows ss som a ma a s vo s ss pa st s a som o c t mo s v t go

s ato y yst m st ma dysp a

a d ag s op c a p otos s t v ty s w at g c as d

Sp c a S s s d v s o

U og ta Syst m yst t s dys a mat a t st t a p ts o g a/po y a p ot a a fa

t adv s act o s pat ts ta g NS I s w c occ a y a

ody as a W o ap y act c act o s app t t c a g s d at

a d o asc a yst m yt m a ypot s o myoca d a facto pa p tat o s vasc ts

g st v yst m o t s c ato v fa pa c atts

m c a d ymp atc Syst m g a ocy oss moyt c a ma ap ast c a ma ymp ad opat y pa cytop a

M tabo c a d N t t o a yp g yc ma

o s yst m o v so s coma a c ato s m gts

sp ato y Syst m sp ato y d p sso p mo a

S a d pp dag s g o d ma tox c p d ma c o y s s yt ma m t fo m x o at v d matts St v s o so sy d om t ca a

Sp c a S s s o ct v t s a g mpa m t

7 DRUG IN ER CTIONS

7.1 Aspirin

W adm st d w t asp d c of ac potass m s p ot b d g s d c d c ca s g fica c of t s t acto s ot ow ow v as w t ot NS I s co com ta t adm st ato of c of ac otass m fo a So to a d asp s ot g a y comm d d b ca s of t pot ta of c as d adv s ff c s

7 2 Anticoagulants

f cts of a t coag a ts s c as wa a a d NS I s o I b d g a sy g st c s c t at s s of bot d gs og t av a s of s o s I b d g g t a t at w t s of t d g a o

7 3 CE Inh bitors

NS I s may d m s t a t yp t s v ff ct of b to s s t acto s o d b g v co s d ato pat ts ta g c of ac otass m o a So to co com ta t y w t b o s

7 4 Diuretics

ca st d s as w as post ma t g obs vat o s av s ow t at d c of ac potass m ca d c t at t c ff ct of f os m d a d t az d s som pat ts s spo s as b att b t d o b to of a p ostag a d sy t ss g co com ta t t apy w t NS I s obs v pat ts co s y fo s g s of a fa as w as to ass d t c ficacy *[see* **Warnings and Precautions (5 6)***]*

7 5 Lithium

NS I s av p od c d vat o s of p asma t m v s a d a d cto a t m c a a c m a m m m t m co c t ato c as d 5% a d t a c a a c was d c as d y app ox mat y 20% s f cts av b att b t d to b to of a p ostag a d sy t ss by t NS I W c of ac otass m fo a So to a d t ma adm st d co c ty obs v pat ts ca f y fo s g s of t m tox c ty

This label may not be the latest approved by FDA.
For current labeling information, please visit https://www.fda.gov/drugsatfda

7.6 Methotrexate

NS I s av b po t d o comp ttv y b tm t ot xat acc m ato abb t d ys c s s d cat s t at NS I s may a c t tox c ty of m t ot xat Us ca to w NS I s a adm st d co com a t y wt m t ot xat

7.7 Cyclosporine

c of ac o ass m fo a So to ot NS I s may aff ct a p os ag a d s a d c as t ox c ty of c ta d gs o co com ta t t apy wt c of ac otass m fo a So to may c as cyc ospo s p o ox c ty Us ca to w c of ac otass m fo a So to s adm st d co com a t y wt cyc ospo

7.8 Inhibitors of Cytochrome P450 2C9

c of ac s m tabo z d p dom a ty by yoc om 50 Y 2 9 o adm st ato of m d cato s t at b t Y 2 9 may aff ct t p a maco t cs of d c of ac *[see* **Cl nical Pharmacology (12 3)***]*.

8 USE IN SPECIFIC POPULA IONS

8.1 Pregnancy

Pregnancy Category C prior to 30 weeks gestation; Category D starting at 30 weeks gestation.

Sta t g at 30 w s g stat o c of ac otass m fo a So to a d ot NS I S s o d b avo d d y p g a t wom as p mat c os of t d ct s a t os s t f t s may occ *[see* **Warn ngs and Precautions (5 9)***]*. a o ad q at a d w co to d st d s p g a t wom

o to 30 w s g s ato c of ac otass m fo a So to s o d b s d d g p g a cy o y f t pot t a b fit st fi s t pot ta s to t f t s

p od ct v st d s av b p o m d m c g v d c of ac sod m p to 20 mg/ g/day 2 t m s t comm d d ma dos [ ] of 50 mg/day o a body s fac a a [mg/m² bas s a d ats a d abb s g v d c of ac sod m p to 0 mg/ g/day 2 [ats] a d [abb ts] t m s t o a mg/m² bas s a d av v a d o vd c of t a og c ty d spt t d cto of mat a tox c ty a d f ta ox c ty I ats mat a y ox c dos s w assoc at d wt dystoc a p o o g d g stat o d c d f ta w g ts a d g owt a d d c d f ta s vva

8.2 Labor and Delivery

ff c s of c of ac o ass m fo a So to o abo a d d v y p g a t wom a ow I at st d s mat a xpos to NS I s as wt ot d gs ow to b t p ostag a d sy t ss c as d t c d c of dystoc a d ay d pa t to a d d c as d p ps vva

8.3 Nursing Mothers

It s ot ow w t t s d gs xc t d ma m ca s ma y d gs a xc t d ma m a d b ca s of t pot ta fo s o s adv s acto s s g fa ts f om c of ac o ass m fo a So to a d c so s o d b mad w t to d sco t s g o to d sco t t d g ta g to acco t t mpo ta c of t d g to t mot

8.4 Pediatric Use

Saf ty a d ff ct v ss p d at c pat ts av ot b stab s d

8.5 Geriatric Use

ca st d s of c of ac o ass m fo a So to d d ot c d s ffic t mb s of s b c s ag d 65 a d ov o d t m w t t y spo d d ff t y f om yo g s b cts

d y pat s a at c as d s fo s o s I adv s v ts

c of ac s ow to b s bsta t a y xc t d by t d y a d t s of adv s acto s o t s d g may b g at pat ts wt mpa d a f cto ca s d y pat s a mo y o av d c as d a f cto ca s o d b a w s g c of ac otass m fo a So to t d y

8.6 Hepatic Impairment

ca s pat c m tabo sm acco ts fo a most 00% of d c of ac m ato pat ts wt pat c mpa m t s o d b co s d d o t atm t wt c of ac o ass m o a So to o y f t b fis o tw g t s s s s ffic t o mato ava ab o s ppo t dos g comm dat o s fo c of ac otass m o a So to pat ts wt pat c s fic cy *[see* **Clinical Pharmacology (12 3)***]*.

8.7 Renal Impairment

No fo mat o s ava ab f om co t o d c ca st d s ga d g t s of c of ac o ass m o a So to pat s wt adva c d a d s as fo t atm t wt c of ac otass m fo a So to s ot comm d d pat ts wt adva c d a d s as If c of ac otass m fo a So to t apy m st b tat d c os mo o g of t pat ts a f cto s adv sab

0 OVERDOSAGE

ymptoms o ow g ac t NS I ov dos s a s a y m t d o t a gy d ows ss a s a vom t g a d p gast c pa w c a g a y v sb wt s ppo t v ca ast o t st a b d g ca occ yp t so ac t a fa sp ato y d p sso a d coma may occ b t a a ap y acto d acto s av b po t d wt t ap t c g sto of NS I s a d may occ fo ow g a ov dos

at ts s o d b ma ag d by symp omat c a d s ppo t v ca fo ow g a NS I ov dos a o sp c fic a t dot s m ss a d o act vat d c a coa 60 to 00 g ad s to 2 g/ g c d a d/o osmot c cat a t c may b d cat d pat ts s wt o s of g sto wt symptoms o fo ow g a a g ov dos 5 to 0 t m s t s a dos o c d d ss a a zat o of mod a ys s o mop f s o may ot b s f d o g pot b d g

11 DESCR PT ON

c of ac otass m fo a So to s a b z ac t c ac d d vat v NS I c of ac otass m fo a So to s ava ab as a flavo d so b powd d s g d to b m x d wt wat p o o o a adm st at o

c of ac otass m fo a So to s a w t to o f w t flavo d powd o o a so to pac ag d d v d a t dos pac ts *[see* **HOW SUPPL ED/S ORAGE AND HANDLING (16)***]*.

c m ca am fo d c of ac potass m s 2 [2 6 d c o op y am o] b z ac t c ac d mo opotass m sa t mo c a w g t of d c of ac po ass m s 33 25 Its mo c a o m a s ₂NK ₂ a d t as t o ow g st ct a fo m a



act v g d ts c of ac otass m fo a So to c d spa tam q va t to 22 5 mg p y a a p pp m t flavo g yc y b at ma o po ac a potass m a d sacc a sod m

2 CLIN CAL PHARMACOLOGY

2.1 Mechanism of Action

c of ac otass m o a So to s a o st o da a t flammato y d g NS I m c a sm of acto of c of ac o ass m fo a So to t at of ot NS I s s ot comp t y d stood b t may b at d o p ostag a d sy t tas b to

2 3 Pharmacokine ics

bso pt o c of ac s 00% abso b d aft o a adm st at o compa d to t av o s adm st at o as m as d y cov y ow v d to fi st pass m tabo sm o y abo t 50% of t abso b d dos s syst m ca y ava ab I fast g vo t s m as ab p asma v s w obs v d wt 5 m t s of dos g wt c of ac otass m o a So to a p asma v s w ac v d at app ox mat y 0 25 o fast g o ma vo t s wt a a g of 0 to 0 6 o s g fat food ad o s g fica t ff ct o t xt t of d c of ac abso pt o b t t was a d ct o p a p asma v s of app ox mat y 0% aft a g fat m a c as d $_{m\,x}$ may b assoc at d o d c as d ff ct v ss

st b to appa t vo m of d st b to V/ of d c of ac potass m s 3 / g

c of ac s mo t a 99% bo d to ma s m pot s p ma y to a b m S m pot b d g s co sta t ov t co c t at o a g 0 5 to 05 mcg/m ac v d wt comm d d dos s

ta o sm v d c of ac m abo t s av b d t fi d ma p asma a d m abo t s c d yd oxy 5 yd oxy 3 yd oxy 5 d yd oxy a d 3 yd oxy m t oxy d c of ac ma o d c of ac m tabo t yd oxy d c of ac as v y w a p a maco og c act v ty fo mat o of yd oxy d c of ac s p ma y m d at d by Y2 9 ot d c of ac a d ts ox dat v m tabo t s d go g c o dat o s fat o o ow d by b a y xc to cy g c o dat o m d at d by U 2 a d ox dat o m d at d by Y2 8 may a so p ay a o d c of ac m abo sm Y 3 s spo s b fo t fo mat o of m o m tabo t s 5 yd oxy a d 3 yd oxy d c of ac I pat ts wt a mpa m t p a co c t at o s of m abo t s yd oxy a d 5 yd oxy d c of ac w app ox mat y 50% a d % of t pa t compo d at s g o a dos g compa d o 2 % a d % o ma at y s b c s

xc to c of ac s m at d t o g m tabo sm a d s bs q t a y a d b a y xc to of t g c o d a d t s fat co gat s of t m abo t s tt o of c a g d d c of ac s xc t d t pp ox mat y 65% of t dos s xc t d t a d app ox mat y 35% t b as co gat s of c a g d d c of ac p s m tabo t s ca s a m ato s ot a s g fica t pat way of m ato o c a g d d c of ac dos g ad stm t pat ts wt m d to mod at a dysf cto s ot c ssa y t m a af f of c a g d d c of ac s app ox mat y 2 o s

ca o ato s

Race: a o p a maco t c d ff c s d to ac

Hepatic Impairment: v m abo z s a most 00% of d c of ac t s s ffic t o mato ava ab o s ppo t dos g comm dat o s fo c of ac o ass m fo a So to pat ts wt pat c s ffic cy 5 3 8 6

Renal Impairment: I pat ts wt a mpa m t c a a c 60 to 90 30 to 60 a d 30 m /m N=6 ac g o p U va s a d m ato at w compa ab to t os at y s b c s

3 NON CLIN CAL STUDIES

3.1 Carcinogenesis, Mutagenesis, Impairment of Fert lity

o g t m ca c og c ty st d s ats g v d c of ac sod m p to 2 mg/ g/day ss t a t comm d d ma dos [ ] of 50 mg/day o a body s fac a a [mg/m²] bas s av v a d o s g fica t c as s t mo c d c was a s g t c as b g mamma y fib oad omas m d dos t at d 0 5 mg/ g/ day o 3 mg/m²/day f ma ats g dos f ma s ad xc ss v mo ta ty b t t c as was ot s g fica t o t s commo at t mo 2 y a ca c og c ty st dy co d ct d m c mp oy g d c of ac sod m at dos s p to 0 3 mg/ g/day ss t a t o a mg/m² bas s ma s a d m/ g/day ss t a t o a mg/m² bas s f ma s d d ot v a a yo cog c pot ta

c of ac sod m was ot g otox c *in vitro* v s m ato bact a [m s] mo s ymp oma t o *n vivo* c d g dom a t t a a d ma g m a pt a c omosoma ab ato s amst assays

c of ac sod m adm st d to ma a d f ma a s at mg/ g/day ss t a t o a mg/m² bas s d d ot a f ct f t ty

14 CLIN CAL STUDIES

fficacy of c of ac otass m fo a So to t ac t t atm t of m g a adac was d mo st at d two a dom z d do b b d p ac bo co to d t a s

at ts o d t s two t a s w p dom a t y f ma 85% a d w t 86% wt a m a ag of 0 y a s a g 8 to 65 at s w st ct d to t at a m g a of mod at to s v pa wt dos of st dy m d cat o at ts va at d t adac pa 2 o s at ssoc at d symp oms of a s a p otop ob a a d p o op ob a w a so va at d I add to t p opo to of pat ts w o w s sta d pa f d fi d as a d cto adac s v ty f om mod at o s v pa to o pa at 2 o s post dos wt o t a t of m d mod at o s v pa a d o s of sc m d cat o fo 2 o s post dos was a so va at d I t s st d s t p c tag of pat ts ac v g pa f dom 2 o s aft t atm t a d s sta d pa f dom f om 2 o 2 o s post dos was s g fica t y g at pat ts w o c v d c of ac otass m o a So to compa d wt t os w o c v d p ac bo s **able 2** p c tag of pat ts ac v g pa f 2 o s aft t atm t d fi d as a d cto adac s v ty f om mod at o s v pa to m d o o pa was a so s g fica t y g at pat ts w o c v d c of ac otass m fo a So to compa d wt t os w o c v d p ac bo s **able 2**

Table 2: Percentage of Patients With 2 Hour Pain Freedom, Sustained Pain Freedom 2 o 24 Hours, and 2 Hour Pain Relief Fo lowing T eatment

Study 1	**Diclofenac Potassium for Oral Solution (n=265)**	**Placebo (n 257)**
2-Hour Pain Free	2 %	13%
2-2 h Sustained Pain Free	22%	10%
2-Hour Pain Relief	8%	27%
Study 2	**Diclofenac Potassium for Oral Solution (n=343)**	**Placebo (n 347)**
2-Hour Pain Free	25%	10%
2-2 h Sustained Pain Free	19%	7%
2-Hour Pain Relief	65%	1%

st mat d p obab ty of ac v g m g a adac pa f dom wt 2 o s fo ow g t atm t wt c of ac otass m o a So to s s ow **Figure 1**

Figure 1. Percentage of Patients With Initial Headache Pain Freedom Within 2 Hours



was a d c as d c d c of a s a p otop ob a a d p o op ob a fo ow g adm st at o of c of ac otass m fo a So to compa d to p ac bo fficacy a d saf ty of c of ac o ass m fo a So to was aff ct d by ag o g d of t pat t

6 HOW SUPPLIED/STORAGE AND HANDLING

c of ac otass m fo a So to 50 mg s s pp d as d v d a dos pac ts ac d v d a pac t s d s g d to d v a dos of 50 mg d c of ac po ass m w m x d wat

c of ac otass m fo a So to s a w t to o f w t flavo d powd o o a so to pac ag d d v d a t dos pac ts

I d v d a c of ac otass m o a So to ac t N 988 905 52

ox s of t 3 c of ac otass m fo a So to ac ts N 988 905 2

ox s of 9 c of ac otass m fo a So to ac ts N 988 905 6

Sto at 25 xc s o s p m tt d f om 5 to 30 59 to 86 [S US o t o d oom mp at]

17 PA IENT COUNSELING INFORMAT ON

I fo m pat ts of t ava ab ty of a M d cat o d fo NS I s t at accompa s ac p sc pt o d sp s d a d st ct t m to ad t M d cat o d p o to s g c of ac otass m fo a So to *[see* **Medica tion Guide (17 9)***]*.

17.1 Cardio ascular Effects

c of ac otass m fo a So to ot NS I S may ca s s o s V v ts s c as MI o st o w c may s t osp ta zat o a d v d at t o g s o s V v s ca occ wt o t wa g symptoms adv s pat s o b a t o t sg s a d symptoms of c st pa s o t ss of b at w a ss s g of sp c a d o as fo m d ca adv c w obs v g a y d cat v s g o symptoms I fo m pat ts of t mpo ta c of t s fo ow p *[see* **Warnings and Precautions (5 1)***]*.

17 2 Gastrointestinal E fects

c of ac otass m fo a So to ot NS I S ca ca s I d scomfo t a d mo s o s I adv s v ts s c as c s a d b d g w c may s t osp ta zat o a d v d at t o g s o s I t act c at o s a d b d g ca occ wt o t wa g symptoms adv s pat s o b a t o t sg s a d symptoms of c at o s a d b d g a d to as fo m d ca adv c w obs v g a y d cat v s g o symptoms c d g p gast c pa dysp ps a m a a d mat m ss I o m pat s of t mpo ta c of t s o ow p *[see* **Warnings and Precautions (5 2)***]*.

17 3 Hepato o icity

I fo m pat s of t wa g s g s a d symp oms of patotox c ty g a s a fat g t a gy p t s a d c g t pp q ad a t t d ss a d fl symptoms I st ct pat ts to stop t a y wt c of ac otass m fo a So to a d s mm d at m d ca t apy f a y of t s occ *[see* **Warnings and Precautions (5 3)***]*.

17.4 Weight Gain and Edema

dv s pat ts to p ompt y po t to t p ys c a s s g s o symp oms of xp a d w g t ga o d ma d g t atm t wt c of ac o ass m fo a So to *[see* **Warnings and Precautions (5 5)***]*.

17.5 Anaphylactoid Reactions

I fo m pat s of t s g s of a a ap y acto d act o g d fic ty b at g sw g of t ac o t oat I st ct pat s to s mm d at m g cy p f t s occ *[see* **Warnings and Precautions (5 7)***]*.

17.6 Adverse Skin Reactions

c of ac o ass m o a So to ot NS I S ca ca s s o s acto s s c as xfo at v d mat t s St v s o so sy d om S S a d tox c p d ma c os s N w c may s t osp ta zat o s a d v d at t o g s o s s act o s may occ wt o t wa g adv s pat ts to b a t fo t s g s a d symptoms of s as a d b st s f v o ot s g s of yp s s t v ty s c as tc g a d to as o m d ca adv c w obs v g a y d cat v s g s o symp oms dv s pat ts to stop c of ac otass m fo a So to mm d at y f t y d v op a y typ of as a d to co act t p ys c a s as soo as poss b *[see* **Warnings and Precautions (5 8)***]*.

17.7 E fects During Pregnancy

S a t g at 30 w s g stat o c of ac otass m fo a So to a d ot NS I s s o d avo d d by p g a t wom as p mat c os of t d ct s a t os s t f t s may occ *[see* **Use in Specific Popu ations (8 1)***]*

17.8 Pheny ketonurics

c of ac otass m fo a So to co ta s y a a 22 5 mg p ac 50 mg pac t

17.9 FDA Approved Medication Guide

Upo d sp s g to a pat t p as s t pat t c v s t attac d M d cat o d

MEDICAT ON GUIDE
DICLOFENAC POTASSIUM for oral solution
dye KLOE fen ak poe-TAS ee um

ad t at t I o mat o t at com s wt c of ac otass m o a So to b fo yo sta t a g t a d ac t m yo g t a fi may b w fo mat o s af I t do s ot ta t p ac of ta g wt yo doc o abo t yo m d ca co d t o o yo t atm t

What is the most mportant information I should know about Diclofenac Potassium for Oral So ution?

Diclofenac Potassium for Oral So ution, which contains dic ofenac, (a non-steroidal anti-inflammatory drug or NSAID) may increase your chance of a heart attack or stroke that can lead to death his chance is higher:

- wt o g s of NS I m dc s
- p op w o av a t d s as

NSA D medicines such as Diclofenac Potassium for Oral Solution shou d never be used right before or after a heart surgery ca led a "coronary ar ery bypass graft" CABG)

NSA D medic nes such as Diclo enac Potassium for Oral Solu ion can cause ulcers and bleeding in your stomach and intestines at any time during treatment

Ulcers and b eeding:

- ca app wt o t wa g symptoms
- may ca s d at

he chance of a person gett ng an u cer or bleeding increases w th:

- t s of m d c s ca d st o d o mo s co t cost o ds a d b ood t s a t coag a ts
- o g o g a s
- smo g
- d g a co o
- o d ag
- av g poo a t

Diclofenac Potass um for Oral Solution should only be used:

- xact y as p sc b d
- at t ow st dos poss b fo yo t atm t
- fo t s o t st t m d d

What is Diclofenac Potass um for Oral Solution?

c of ac otass m fo a So to s a p sc pto m d c s d to t at m g a a tac s ad ts It do s ot p v to ss t mb of m g a s yo av a d t s ot fo ot typ s of adac s c of ac otass m fo a So to co ta s d c of ac po ass m a No St o da t I flammato y g o NS I

How shou d I take Diclofenac Potassium for Oral Solu ion?

a c of ac o ass m fo a So to xact y as yo at ca p ov d t s yo to a t

a dos of c of ac otass m fo a So to to t at yo m g a adac

- mov o s g dos pac t f om a s t of t pac ts
- op pac t o y w yo a ady to s t
- mpty co t s of pac t to to 2 o c s 2 o ab spoo s of wat
- m x w a d d t wat a d powd m xt
- t ow away mpty pac t a saf p ac a d o t of t ac of c d
- ta g c of ac otass m o a So to wt ood may ca s a d cto ff ct v ss compa d to ta g c of ac otass m o a So to o a mpty stomac
- do ot ta mo c of ac otass m fo a So to t a d ct d by yo at ca p ov d I cas of ov dos g t m d ca p o co tact a o so o to t g t away

Who shou d not ake Diclofenac Potassium for Oral So ution?

o ot ta c of ac otass m fo a So to

- g t b fo o aft a t bypass s g y S W at s t most mpo ta t o mat o I s o d ow abo t c of ac otass m o a So to
- f yo av o av ad a ast ma attac v s o ot a g c acto wt asp d c of ac o a y ot NS I m d c

Before you ake Diclofenac Potassium for Oral Solution tell your healthcare provider about a yo m d ca co d t o s c d g f yo

- av a s o y of stomac c o b d g yo stomac o t st s
- av d y o v p ob ms
- av a y a g s o a y m d c s
- av c st pa s o t ss of b at g a a t b as
- a p g a t t yo m g t b p g a t o a t y g to b com p g a t c of ac o ass m fo a So to s o d ot b s d by p g a t wom sp c a y d g t ast 3 mo t s of p g a cy ss d ct d by yo at ca p ov d to do so c of ac otass m o a So to may ca s p ob ms yo bo c d o comp cat o s d g yo d v y
- a b astf d g o pa to b as f d It s ot ow f c of ac otass m pass s to yo b ast m Yo a d yo doc o s o d d c d f yo w ta c of ac otass m fo a So to o b astf d Yo s o d ot do bot
- av a adac t at s d f t f om yo s a m g a

ell your doctor about all the med c nes you take c d g p sc pto a d o p sc pto m d c s v ta m s a d ba s pp m ts

c of ac otass m o a So to a d ot m d c s may aff ct ac ot ca s g s d ff cts c of ac otass m fo a So to may aff ct t way ot m d c s wo a d ot m d c s may aff ct ow c of ac otass m o a So to wo s

Espec ally ell your doctor if you take:

- asp
- a y a t coag a t m d c s wa fa o mad a tov

K ow t m d c s yo a K p a st of yo m d c s a d s ow t to yo docto a d p a mac st w yo g t a w m d c

What are the poss ble side effects of Diclofenac Potassium for Oral Solution?

Serious side effects include:

- a t at ac
- st o
- g b ood p ss
- a t fa f om body sw g fl d t to
- d y p ob ms c d g d y fa
- b d g a d c s t stomac a d t st
- ow d b ood c s a ma
- f t at g s act o s
- f t at g a g c act o s
- v p ob ms c d g f t at g v fa
- ast ma a tac s p op w o av ast ma

Get emergency he p r ght away if you have any of the following symptoms of heart attack or stroke:

- s o t ss of b at o t o b b at g
- c st pa
- sw g of yo ac o t oat
- w a ss o pa t o o s d of yo body
- s d sp c

Common s de e fects include:

- a s a
- d zz ss

Stop Diclofenac Potassium for Oral Solution and call your healthcare provider right away if you have any of the following symptoms:

- a s a t at s ms o t of p opo to o yo m g a
- stomac pa
- s dd o s v pa yo b y
- vom t b ood
- b ood yo bow mov m t o t s b ac a d st c y ta
- tc g
- s as o b st s wt f v
- y ows o y s
- sw g of yo a ms a d gs a ds a d f t
- s a w g t ga
- mo t d o w a t a s a
- fl symptoms

yo at ca p ov d f yo av a y s d f cts t at bot yo o do ot go away

s a ot a t s d f cts wt NS I m d c s a to yo at ca p ov d o p a mac st fo mo fo mat o abo t NS I m d c s

a yo at ca p ov d fo m d ca adv c abo t s d ff c s Yo may po t s d ff cts o at 800 088

How shou d I store Diclo enac Potass um for Oral Solution?

- sto c of ac o ass m fo a So to a d y p ac at oom t mp at b tw 59 to 86 5 to 30
- p c of ac o ass m fo a So to a d a m d c s o t of ac of c d

General nformation about Diclofenac Potassium for Oral So ution

- m d c s a som t m s p sc b d fo p pos s ot t a t os st d a M d cat o d o ot s c of ac otass m o a So to fo a co d t o o w c t was ot p sc b d
- do ot g v c of ac otass m fo a So to o ot p op v f t y av t sam p ob m yo av It may a m t m
- t s M d cat o d co ta s t most mpo ta t fo mat o abo t c of ac otass m fo a So to If yo wo d mo fo mat o ta wt yo at ca p ov d Yo ca as yo at ca p ov d fo fo mat o w t fo at ca p of ss o a s
- fo mo fo mat o ca a a mac t ca I c at 800 28 9393

What are the ingredients in Diclofenac Po ass um for Oral So ution?

Active ngred ents: c of ac po ass m

Inactive ingred ents: spa am q va t to 22 5 mg p y a a p pp m t flavo g yc y b at ma to po ac a po ass m a d sacc a sod m

x o y

st b t d y
Par Pharmaceutical Companies nc
st t dg NY 09 U S

Ma act d by
Par Formulations Priva e Limited
/58 d pa am
K amba am 603 03
Mad I d a

Mfg c No N00002 2
I0 / 5

S905 0 0
S 53 /00

his Medication Guide has been approved by the U S Food and Drug Administration